

Appl. No. 10/082,691

Reply to Office Action of December 28, 2004

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A method for treating neurogenic inflammation pain, the method comprises administering a therapeutically effective amount of about 0.01 units to about 1,000 units of an agent to a patient, the agent comprising a botulinum toxin ~~component covalently coupled to a substance P component~~ proteolytic domain, a botulinum toxin translocation domain coupled to the proteolytic domain, and a substance P component covalently coupled to the botulinum toxin translocation domain, the substance P component being effective in binding to a substance P receptor, thereby treating the neurogenic inflammation pain for at least about two months.

2. (Currently amended) The method of claim 1 wherein the botulinum toxin ~~component comprises an L chain or an HN and an L chain~~ proteolytic domain is an L chain of a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C, serotype D, serotype E, serotype F and serotype G.

3. (Currently amended) The method of claim ~~[[2]]~~ 1 wherein the ~~HN is obtained from a~~ botulinum toxin translocation domain is an HN portion of a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C, serotype D, serotype E, serotype F and serotype G.

Appl. No. 10/082,691

Reply to Office Action of December 28, 2004

4. (Currently amended) The method of claim 2 wherein the ~~HN is obtained from botulinum toxin serotype A~~ proteolytic domain is an L chain of a botulinum toxin serotype A.

5. (Cancelled)

6. (Currently amended) The method of claim ~~[[2]]~~ 3 wherein the ~~L chain is obtained from botulinum toxin serotype A~~ translocation domain is an HN portion of a botulinum toxin serotype A.

7. (Previously presented) The method of claim 1 wherein the substance P component is substance P.

8. (Previously presented) The method of claim 1 wherein the substance P component is a precursor of substance P having an amino acid sequence selected from the group of consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10.

9-11. (Cancelled)

12. (Original) The method of claim 1 wherein the pain is arthritis pain.

13-16. (Cancelled)

17. (Previously presented) The method of claim 1 wherein the agent is administered subcutaneously.

Appl. No. 10/082,691
Rcply to Office Action of December 28, 2004

18. (Previously presented) The method of claim 1 wherein the agent is administered intramuscularly.

19. (Currently amended) The method of claim 1 wherein the agent is administered ~~systemically~~ to a site of the pain.

20-21. (Cancelled)

22. (Previously presented) The method of claim 1 wherein the agent is administered in an amount from about 10^{-2} U/kg to about 100 U/kg.

23. (Previously presented) The method of claim 1 wherein the agent is administered in an amount from about 10^{-1} U/kg to about 10 U/kg.

24. (Previously presented) The method of claim 1 wherein the agent is administered in an amount from about 1 unit to about 20 units.

25. (Previously presented) The method of claim 1 wherein the agent is administered in an amount from about 1 unit to about 10 units.

26. (Previously presented) The method of claim 1 wherein the agent is administered in an amount from about 0.1 U/kg to about 30 U/kg.

27-29. (Cancelled)